Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-15

Study Completion Date

2021-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Context:

Based on currently available data, most of national health authorities and consensus expert groups have written guidelines for the management of cancer patients in the context of COVID. However, the preparation of these guidelines was limited by the scarcity of solid epidemiological data. For example, the experts were uncomfortable to formulate precise guidelines on which anti-cancer treatment should be interrupted or replaced, on which patients, and how to adapt supportive drug prescriptions.

Objectives :

* To measure the excess risk of mortality and morbidity of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection.
* To identify factors associated with the risk of death and morbidity among patients with cancer.

Methodology:

Retrospective inclusion of n=200 cancer patients hospitalized for COVID and n=400 matched (based on age, gender, and comorbidity) non-cancer patients hospitalized for COVID. Two analyses will be performed (after the inclusion of n=100 and n=200 patients with cancer). A logistic modeling of the odds ratio of death associated to the exposition factor (i.e. cancer) and adjusted for the matching parameters (age, gender, comorbidities) will be proposed.

We will then look for the factors (related to the patients, the cancer or the treatment) that modify the odds radio.

Expected results:

The data generated will help the medical and scientific community to evaluate the increasing risk of cancer patients infected by SARS-CoV-2 compared to the non-cancer population, to identify patients at higher risk of severe infection, but also the anticancer treatments associated with an increased risk of severe infections.

Impact:

These data will contribute to guide the future recommendations concerning cancer patient's care in the context of the COVID-19 pandemic. There is a real risk that the SARS-CoV epidemic, or other respiratory viruses epidemic, will become recurrent in the future. Thus, it is of crucial importance for now and for the future to know which are the major factors associated with severe infections

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Medical Treatment of Solid Tumors at the Lyon University Hospital Cancer Institute During the First Wave of COVID-19 in France: A Conservative Approach

NCT04910633

Cancer Solid Tumor Covid19

COMPLETED

Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic

NCT04421625

COVID-19

COMPLETED NA

Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic

NCT04340219

Cancer

COMPLETED

Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic

NCT04464486

Oncology

COMPLETED NA

Quality of Life and Cancers in Nursing Homes

NCT03343210

Quality of Life Cancer Nurse's Role

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID, Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

exposed patients

The "exposed patients" are patients with cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection. A patient will be considered as an "exposed patient" if he/she had a surgical procedure or a medical treatment for cancer in the past 5 years preceding the SARS-CoV-2 infection.

mortality

Intervention Type OTHER

To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection

control patients

The "control patients " are all of the patients without cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection

mortality

Intervention Type OTHER

To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mortality

To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* EXPOSED PATIENTS:
* Age \> 18 years old
* Patients with a confirmed diagnosis of solid or hematologic cancer
* Patients who received their last anticancer treatment (surgery, systemic treatments or other localized treatment) in the past 5 years before SARS-CoV-2 infection
* Positive laboratory test (RT-PCR) proving the SARS-CoV-2 infection
* Patients hospitalized in one of the participating centers because of the SARS-CoV-2 infection
* Patients who are not opposed in participating to the ONCOVID-AURA study

CONTROL PATIENTS:

* Age \> 18 years old
* Patients who have no cancer (neither solid nor hematologic tumors) or patients who received their last anticancer treatments more than five years before the SARS-CoV-2 infection
* Positive laboratory test (RT-PCR) proving the SARS-CoV-2 infection
* Patients hospitalized in one of the participating centers because of the SARS-CoV-2 infection
* Patients who are not opposed in participating to the ONCOVID-AURA study